Gennex Laboratories Ltd (GENNEX) is currently trading at 10.14 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Gennex Laboratories Limited specializes in manufacturing and exports active pharmaceutical ingredients (APIs) and intermediates, focusing on expectorants, muscle relaxants, analgesics, and antifungal products. The company maintains a global footprint with exports to countries including Germany, UK, Spain, Singapore, Canada, and more, marking its prominence in international markets. It has a vertically integrated business model, enhancing operational efficiencies and product diversification. In 2023, Gennex acquired a 51% share in Deccan Remedies Limited, indicating a strategic move to expand its business scope. The company emphasizes compliance with GMP standards and CGMP guidelines, showcasing its commitment to quality and industry best practices.

Over the past 52 weeks, Gennex Laboratories Ltd has traded between a low of ₹9.92 and a high of ₹17.25. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Gennex Laboratories Ltd has a market capitalization of approximately 246.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Gennex Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 13.32 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 246.35 Cr, Gennex Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Gennex Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Gennex Laboratories Ltd is 13.32. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.